Anavex Life Sciences Corp (AVXL)

[blu_1]

From Anavex's AAIC poster summary:
"Despite the relatively small sample size of this proof-of-concept,
randomized, open-label study with oral daily doses (not optimized) of
ANAVEX 2-73 ranging from 10mg to 50mg, data seems to indicate a
converging and consistent response for all measurements (MMSE,
ADCS-ADL, Cogstate, EEG/ERP) currently throughout 31 weeks (7
months) of ANAVEX 2-73 treatment."

As the quote above states, the patients have been on NON-OPTIMIZED dosages of 10-50mg. Imagine how much better their scores would be had they all been receiving 50mg every day from day one of Ph 2. Imagine how much better their scores would be had 273 not been having to compete for receptor sites with already spent donepezil. Donepezil has MUCH greater affinity for the sigma sites and its effect on the muscarinic sites is the exact opposite effect as 273. A paper posted here couple months ago showed muscarinic antagonists, like donepezil, actually thwart, counter, and dampen the beneficial effects of muscarinic agonists, such as 273. If anyone has link to that paper please post here.

My point is, don't expect improvement or stabilization of scores at 9 or 12 months at CTAD. That's now fair to 273. Be realistic and logical. Ignore the non scientists that don't take the aforementioned into account.